scispace - formally typeset
C

Chris Sander

Researcher at Harvard University

Publications -  730
Citations -  273726

Chris Sander is an academic researcher from Harvard University. The author has contributed to research in topics: Large Hadron Collider & Protein structure. The author has an hindex of 178, co-authored 713 publications receiving 233287 citations. Previous affiliations of Chris Sander include Purdue University & University of Leeds.

Papers
More filters
Journal ArticleDOI

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

TL;DR: The prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer are defined to serve as a platform for therapeutic drug discovery and optimal development of target-specific agents will require pretreatment genomic characterization.
Journal ArticleDOI

Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".

TL;DR: This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in oncology.
Journal ArticleDOI

Dipoles of the alpha-helix and beta-sheet: their role in protein folding.

TL;DR: In this article, the alignment of secondary structure dipoles is shown to be significant in determining the three-dimensional structure of globular proteins, as a result of the regular arrangement of peptide dipoles in secondary structure segments and the low effective dielectric constant in Hydrophobic cores.
Journal ArticleDOI

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Franz X. Schaub, +736 more
- 28 Mar 2018 - 
TL;DR: expression analysis revealed MYC-associated pathways in tumor subtypes, such as immune response and growth factor signaling, and chromatin, translation, and DNA replication/repair were conserved pan-cancer, suggesting that MYC is a distinct oncogenic driver.